SR wow she will f it up

Looks like SR after all the damage done at Tolmar will be effing this place up as well

 

What happened at Tolmar?

 

Ask anyone there- she was a cluster- a complete mess

 

Did she leave voluntarily?

 

Depends on who you ask.
She is a moron! Not sure why they hired her!

 

Speaking of cluster hen she hired Pavicich

 

SR isn’t the sole reason it gets f’ed up. Just look at the sales leadership and you’ll see a disaster waiting to happen.

 

What a complete waste of time and energy this place was. Company is going to implode.

 

you called it although Susan isn’t near as culpable as Mike Raab and his band of Genzyme losers and executive bottom feeders.

since no press release yet will leave this here to the investors they’re not doubt going to continue to try to dupe. Thanks for the layoff announcement today at 8 am PST for the entire commercial organization. Bye bye

 

Good luck in IBS C losers. Got a great whistleblower as a sales leader.

https://www.bafirm.com/result/240-mm-for-the-whistleblowers-and-government-in-settlement-of-drug-testing-claims/

 

Ryan Uehling. What an assclown.

 

It’s not even just Ryan U – the entire leadership team there is full of inept, airhead, losers. From Ryan, Rich, Dan, Sharon, Susan, all the way up to the CEO Mike Raab. They’re all liars. Sharon has her minions that are all yes ma’am’s and cant think for themselves. Dan can’t represent his team to save his life, he just jumps when Sharon or Susan say jump, Rich thinks he is gods greatest gift to that company. The entire leadership team has zero sense of awareness and anyone who thinks they are going to succeed in IBS has lost their mind. Good luck with zero market access, renal reps who don’t even know the GI market, and an overpriced drug.

 

It’s not even just Ryan U – the entire leadership team there is full of inept, airhead, losers. From Ryan, Rich, Dan, Sharon, Susan, all the way up to the CEO Mike Raab. They’re all liars. Sharon has her minions that are all yes ma’am’s and cant think for themselves. Don’t even think about providing them with feedback on what they present or they will chew your head off. Dan can’t represent his team to save his life, he just jumps when people say jump, Rich thinks he is gods greatest gift to that company. The entire leadership team has zero sense of awareness and anyone who thinks they are going to succeed in IBS has lost their mind. Good luck with zero market access, reps who don’t even know the GI market, and an overpriced drug.

 

A few of us had dinner with Susan last summer and she got pretty drunk, it wasn’t a very professional look for someone in the C suite. But then again, she did hire Dan P., so maybe they just sit around and drink together? Dan is also inappropriate when he drinks. He took a bunch of us out during one of his ridiculous road shows and all he takes about/drank was tequila. These are our “leaders.”

 

Still recovering from the wasted meeting in Boston last week. I thought it was bad with my former ZD but Rich brings the bullshit to a new level. At least Brian left us alone

 

This whole place is a dumpster fire and not getting better anytime soon. Guess I’ve got until April to collect the paycheck. Hey Dan P, good thing you don’t actually expect us to work

https://www.fiercebiotech.com/biotech/fda-denies-ardelyx-s-appeal-against-kidney-drug-rejection-hammering-another-nail-tenapanor

 

!!

 

If you think the “launch” of Ibsrela is anything other than a corporate game of kick the can down the street, I’m sorry. We are out here to intro ourselves to GI customers, but they gave us nothing to have any meaningful conversation. Today, one of these GIs told me he doesn’t understand what I’m even doing here with no product to discuss. Embarrassing.
He also showed me an article with the below quote, and said there is zero fit for this product given he’s happy with Linzess, and that he heard we don’t have a partner because no one else sees a value in the drug. So I ask you DAN what the hell are we doing? According to my “top” GI we are fucked.

CEO Michael Raab said that would-be partners for Ardelyx Inc.’s Ibsrela (tenapanor), cleared in September 2019 to treat irritable bowel syndrome with constipation, “don't understand and don't approach the market in the manner that we will,” which is why the company has chosen to launch the sodium/hydrogen exchanger 3 inhibitor on its own in 2022.